Diagnostic utility of anti-Ro52 detection in systemic autoimmunity

Postgraduate Medical Journal

Volumn 86, Issue 1012, 2010, Pages 79-82

  Dugar, Manish ^a   Cox, Sally ^a   Limaye, Vidya ^a   Gordon, Tom Paul ^b   Roberts Thomson, Peter John ^b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; JO 1 ANTIBODY; RHEUMATOID FACTOR; RO52 ANTIBODY; RO60 ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CRYOGLOBULINEMIA; DIAGNOSTIC VALUE; HUMAN; IDIOPATHIC INFLAMMATORY MYOPATHY; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PRIMARY BILIARY CIRRHOSIS; RHEUMATOID ARTHRITIS; SEROPREVALENCE; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; RIBONUCLEOPROTEINS;

EID: 76649140149     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2009.089656     Document Type: Article

References (23)

1. Peene I, Meheus L, De Keyser S, et al. Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis 2002;61: 929-33.
2. Langguth DM, Morris S, Clifford L, et al. Specific testing for "isolated" anti-52kDa SSA/Ro antibodies during standard anti-extractable nuclear antigen testing is of limited clinical value. J Clin Pathol 2007;60:670-3.
3. Hervier B, Rimbert M, Colonna F, et al. Clinical significance of anti-Ro/SSA-52 kDa antibodies: a retrospective monocentric study. Rheumatology 2009;48:964-7.
4. Parker JC, Burlingame RW, Bunn CC. Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis. J Autoimmune Dis 2009;6:2.
5. Koenig M, Fritzler MJ, Targoff IN, et al. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007;9:R78.
6. Frank MB, McCubbin V, Trieu E, et al. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun 1999;12:137-42.
7. Rutjes SA, Vree-Egberts WT, Jongen P, et al. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997;109:32-40.
8. Peene I, Meheus L, Veys EM, et al. Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to detailed serotype. Ann Rheum Dis 2002;61:1090-4.
9. Brouwer R, Hengstman GJ, Vree-Egberts W, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-23.
10. Rhodes DA, Ihrke G, Reinicke AT, et al. The 52000 MW Ro/SS-A autoantigen in Sjögren's syndrome/systemic lupus erythematosus (Ro52) is an interferon-gamma inducible tripartite motif protein associated with membrane proximal structures. Immunology 2002;106:246-56.
11. Wada K, Kamitani T. Autoantigen Ro52 is an E3 ubiquitin ligase. Biochem Biophys Res Commun 2006;339:415-21.
12. Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 2009;8:632-7.
13. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
15. Masi AT, Rodnan GP, Medsger TA Jr, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
16. Targoff IN, Miller FW, Medsger TA Jr, et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997;9:527-35.
17. Vitali C, Bombardieri S, Moutsoupoulos M, et al. Preliminary criteria for the classification of Sjogren's syndrome: results of a prospective concerted action supported by the European community. Arthritis Rheum 1993;36:340-7.
18. Griggs RC, Askanas VA, Dimauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-13.
19. Sherlock S. Primary biliary cirrhosis: clarifying the issues. Am J Med 1994;96(Suppl 1A):27s.
20. Venables PJ. Antibodies to Jo-1 and Ro-52: why do they go together? Clin Exp Immunol 1997;109:403-5.
21. Rhodes DA, Trowsdale J. TRIM21 is a trimeric protein that binds IgG Fc via the B30.2 domain. Mol Immunol 2007;44:2406-14.
22. Sprague ER, Wang C, Baker D, et al. Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol 2006;4:e148.
23. Keech CL, Gordon TP, McCluskey J. The immune response to 52-kDa Ro and 60-kDa Ro is linked in experimental autoimmunity. J Immunol 1996;157:3694-9.